Learn about our management team and the experience that they bring to Hemanext.
President and CEO
Mr. Cannon has served as President, CEO and board member of Hemanext since 2004. Prior to joining Hemanext, Mr. Cannon held senior positions with several leading management consulting firms including 15 years at Bain & Company and A.T. Kearney, which in 1997 acquired Cannon Associates, an international consulting and business development firm founded by Mr. Cannon. As a partner at Bain & Company and with his firm Cannon Associates, Mr. Cannon consulted extensively on growth and innovation strategies in a variety of industries including diagnostic instrumentation, blood banking and hospital management. Mr. Cannon also served as Executive Vice President with Commerce One, Inc., and Group President, Management Consulting with AppNet, Inc. where he was responsible for the development and deployment of software-based decision support platforms. He has served as a Board Member of the National Symphony Orchestra, The Washington Chorus and The US Russia Business Council. He is a graduate of Oxford University.
Chief Scientific Officer
Dr. Dunham serves as Vice President of Research and Clinical Affairs since January 2015. Prior to joining Hemanext, Dr. Dunham held researcher and senior positions at both specialty chemical and healthcare companies including 14 years at Baxter Healthcare. His experience at Baxter included leading the corporate R&D group comprising the global centers for Sterility Assurance, Particle & Imaging, Human Factors & Industrial Design, Pre-clinical, Toxicology, and Histology, Biochemistry and Cell Biology, Organic Synthesis and Analytical Chemistry, Advanced Engineering and Prototyping, and Stability Operations teams. Dr. Dunham has extensive experience applying this broad range of technologies across a diverse range of pharmaceutical and medical device products from development through product support. He is a graduate of the Northern Illinois University, the University of Colorado at Boulder, and had post-doctoral research experience at the University of Colorado Health Sciences Center School of Pharmacy.
Chief Financial Officer
Mr. Newman, a highly experienced start-up company financial executive in the life sciences industry, including three medical device companies, joined the company in 2018. Prior to joining Hemanext, he spent almost 10 years as Director/CFO of TEI Biosciences Inc. (acquired by Integra Lifesciences Corporation for $312M as a wholly-owned subsidiary) managing all the finance, administration and tax requirements for all TEI entities, and successfully achieving a 5X revenue and 15X EBITDA return for all TEI shareholders. Prior to his time in private industry he worked in public accounting for notable firms such as Deloitte & Touche and BDO Seidman. Mr. Newman received his B.S. in Accountancy from Bentley University and is a Certified Public Accountant in the Commonwealth of Massachusetts.
CONNECT WITH HEMANEXT TODAY TO LEARN MORE!
We are happy to answer any questions about the company, our technology, or our research. Fill out the form below and we will connect with you!